| Name | IDO-IN-7 |
| Description | IDO-IN-7 (NLG-919 analogue) is a potent inhibitor of the IDO (indoleamine-(2, 3)-dioxygenase) pathway. |
| In vitro | In mice bearing B16F10 tumors, NLG919 significantly enhanced the antitumor response of pmel-1 resting cells to homologous hgp100 peptide and CpG-1826. |
| In vivo | NLG919 effectively blocks the IDO-induced suppression of T-cell responses, restoring T-cell activity (ED50=80 nM). In mouse dendritic cells (DCs) expressing IDO from tumor lymph nodes (ED50=120 nM), NLG919 abolishes the IDO-induced inhibition of antigen-specific T-cells (OT-1). |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 26 mg/mL (92.07 mM), Sonication is recommended. DMSO : 48 mg/mL (169.98 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (7.08 mM), Sonication is recommended.
|
| Keywords | NLG919 analogue | NLG-919 | NLG 919 | Navoximod analogue | Indoleamine2,3Dioxygenase(IDO) | Indoleamine2,3Dioxygenase | Indoleamine 2,3-Dioxygenase (IDO) | Indoleamine 2,3Dioxygenase (IDO) | Indoleamine 2,3-Dioxygenase | IDO-IN-7 | IDOIN7 | IDO IN 7 | IDO | GDC-0919 analogue | GDC0919 | GDC 0919 |
| Inhibitors Related | Palmatine chloride | GNF-PF-3777 | Coptisine chloride | Necrostatin-1 | TDO-IN-1 | IDO1-IN-28 | Indoximod | Palmatine | Epacadostat | β-Lapachone | IDO-IN-12 | 3-TYP |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Anti-Cancer Metabolism Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immuno-Oncology Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library | Human Metabolite Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |